Stem cell therapies for age-related macular degeneration: the past, present, and future

Yalong Dang,1–3 Chun Zhang,1,2 Yu Zhu31Department of Ophthalmology, Peking University Third Hospital, Beijing, People’s Republic of China; 2Clinical Stem Cell Research Center, Peking University Third Hospital, Beijing, People’s Republic of China; 3Department of Ophthalm...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dang Y, Zhang C, Zhu Y
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Stem cell age-related macular degeneration retinal pigment epithelium clinical trial Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/3a9b46d858a24481932c9ef71d468f4b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3a9b46d858a24481932c9ef71d468f4b
record_format	dspace
spelling	oai:doaj.org-article:3a9b46d858a24481932c9ef71d468f4b2021-12-02T03:04:15ZStem cell therapies for age-related macular degeneration: the past, present, and future1178-1998https://doaj.org/article/3a9b46d858a24481932c9ef71d468f4b2015-01-01T00:00:00Zhttps://www.dovepress.com/stem-cell-therapies-for-age-related-macular-degeneration-the-past-pres-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Yalong Dang,1–3 Chun Zhang,1,2 Yu Zhu31Department of Ophthalmology, Peking University Third Hospital, Beijing, People’s Republic of China; 2Clinical Stem Cell Research Center, Peking University Third Hospital, Beijing, People’s Republic of China; 3Department of Ophthalmology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People’s Republic of ChinaAbstract: In the developed world, age-related macular degeneration (AMD) is one of the major causes of irreversible blindness in the elderly. Although management of neovascular AMD (wet AMD) has dramatically progressed, there is still no effective treatment for nonneovascular AMD (dry AMD), which is characterized by retinal pigment epithelial (RPE) cell death (or dysfunction) and microenvironmental disruption in the retina. Therefore, RPE replacement and microenvironmental regulation represent viable treatments for dry AMD. Recent advances in cell biology have demonstrated that RPE cells can be easily generated from several cell types (pluripotent stem cells, multipotent stem cells, or even somatic cells) by spontaneous differentiation, coculturing, defined factors or cell reprogramming, respectively. Additionally, in vivo studies also showed that the restoration of visual function could be obtained by transplanting functional RPE cells into the subretinal space of recipient. More importantly, clinical trials approved by the US government have shown promising prospects in RPE transplantation. However, key issues such as implantation techniques, immune rejection, and xeno-free techniques are still needed to be further investigated. This review will summarize recent advances in cell transplantation for dry AMD. The obstacles and prospects in this field will also be discussed.Keywords: stem cell, age-related macular degeneration, retinal pigment epithelium, cell reprogramming, clinical trialDang YZhang CZhu YDove Medical PressarticleStem cellage-related macular degenerationretinal pigment epitheliumclinical trialGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 10, Pp 255-264 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Stem cell age-related macular degeneration retinal pigment epithelium clinical trial Geriatrics RC952-954.6
spellingShingle	Stem cell age-related macular degeneration retinal pigment epithelium clinical trial Geriatrics RC952-954.6 Dang Y Zhang C Zhu Y Stem cell therapies for age-related macular degeneration: the past, present, and future
description	Yalong Dang,1–3 Chun Zhang,1,2 Yu Zhu31Department of Ophthalmology, Peking University Third Hospital, Beijing, People’s Republic of China; 2Clinical Stem Cell Research Center, Peking University Third Hospital, Beijing, People’s Republic of China; 3Department of Ophthalmology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People’s Republic of ChinaAbstract: In the developed world, age-related macular degeneration (AMD) is one of the major causes of irreversible blindness in the elderly. Although management of neovascular AMD (wet AMD) has dramatically progressed, there is still no effective treatment for nonneovascular AMD (dry AMD), which is characterized by retinal pigment epithelial (RPE) cell death (or dysfunction) and microenvironmental disruption in the retina. Therefore, RPE replacement and microenvironmental regulation represent viable treatments for dry AMD. Recent advances in cell biology have demonstrated that RPE cells can be easily generated from several cell types (pluripotent stem cells, multipotent stem cells, or even somatic cells) by spontaneous differentiation, coculturing, defined factors or cell reprogramming, respectively. Additionally, in vivo studies also showed that the restoration of visual function could be obtained by transplanting functional RPE cells into the subretinal space of recipient. More importantly, clinical trials approved by the US government have shown promising prospects in RPE transplantation. However, key issues such as implantation techniques, immune rejection, and xeno-free techniques are still needed to be further investigated. This review will summarize recent advances in cell transplantation for dry AMD. The obstacles and prospects in this field will also be discussed.Keywords: stem cell, age-related macular degeneration, retinal pigment epithelium, cell reprogramming, clinical trial
format	article
author	Dang Y Zhang C Zhu Y
author_facet	Dang Y Zhang C Zhu Y
author_sort	Dang Y
title	Stem cell therapies for age-related macular degeneration: the past, present, and future
title_short	Stem cell therapies for age-related macular degeneration: the past, present, and future
title_full	Stem cell therapies for age-related macular degeneration: the past, present, and future
title_fullStr	Stem cell therapies for age-related macular degeneration: the past, present, and future
title_full_unstemmed	Stem cell therapies for age-related macular degeneration: the past, present, and future
title_sort	stem cell therapies for age-related macular degeneration: the past, present, and future
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/3a9b46d858a24481932c9ef71d468f4b
work_keys_str_mv	AT dangy stemcelltherapiesforagerelatedmaculardegenerationthepastpresentandfuture AT zhangc stemcelltherapiesforagerelatedmaculardegenerationthepastpresentandfuture AT zhuy stemcelltherapiesforagerelatedmaculardegenerationthepastpresentandfuture
_version_	1718401977443942400

Stem cell therapies for age-related macular degeneration: the past, present, and future

Ejemplares similares